• Respiratory Drugs, Roflumilast
    Dosage form: Tablet
    Strength: 500mcg
    Indications/Special comments: Adjunct to bronchodilators for the maintenance treatment of patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations.
    Dosage Administration: By mouth: Adult: 500 micrograms once daily.
    View full drug info
  • Neuromuscular Blockers, Rocuronium Bromide
    Dosage form: Injection
    Strength: 10mg/ml
    Indications/Special comments: Neuromuscular blockade (intermediate duration) during surgery and intubation. Neuromuscular blockade (intermediate duration) during intensive care.
    Dosage Administration: Neuromuscular blockade (intermediate duration) during surgery and intubation- Initially by intravenous injection, Adult: Initially 600 micrograms/kg; (by intravenous injection); maintenance 150 micrograms/kg, alternatively (by intravenous infusion) maintenance 300 – 600 micrograms/kg/hour, adjusted according to response. Elderly: Initially 600 micrograms/kg; (by intravenous injection); maintenance 75 - 100 micrograms/kg, alternatively (by intravenous infusion) maintenance up to 400 micrograms/kg/hour, adjusted according to response. Neuromuscular blockade (intermediate duration) during intensive care- Initially by intravenous injection: Adult: Initially 600 micrograms/kg, initial dose is optional; (by intravenous infusion) maintenance 300 – 600 micrograms/kg/hour for first hour, then (by intravenous infusion), adjusted according to response. Doses at extremes of body-weight: To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal bodyweight. For continuous intravenous infusion or via drip tubing may be diluted with Glucose 5% or Sodium Chloride 0.9%.
    View full drug info
  • Keratolytics/Caustics and Antiacne Agents, Retinoic Acid (Tretinoin)
    Dosage form: Cream
    Strength: 0.00025
    Indications/Special comments: Treatment of acne vulgaris, photodamaged skin; palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin as part of a comprehensive skin care and sun avoidance program.
    Dosage Administration: Apply to dry skin, after thorough cleansing, before bedtime. Frequency of application should be individualized.
    View full drug info
  • Keratolytics/Caustics and Antiacne Agents, Retinoic Acid (Tretinoin)
    Dosage form: Ointment
    Strength: 0.0005
    Indications/Special comments: Treatment of acne vulgaris, photodamaged skin; palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin as part of a comprehensive skin care and sun avoidance program.In combination with peginterferon alfa-2a injection for the treatment of chronic hepatitis C in patients with compensated liver disease who were previously untreated with alpha interferons.
    Dosage Administration: Apply to dry skin, after thorough cleansing, before bedtime. Frequency of application should be individualized.
    View full drug info
  • Insulin and Oral Antidiabetic, Repaglinide
    Dosage form: Tablet
    Strength: 0.5mg, 1mg, 2mg
    Indications/Special comments: Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone is inadequate or if transferring from another oral hypoglycaemic drug).
    Dosage Administration: Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate): By mouth. Adult 18 – 74 years: Initially, 500 micrograms (max. per dose 4mg), adjusted according to response, dose to be taken within 30 minutes before main meals and adjusted at intervals of 1 – 2 weeks; maximum 16mg per day. Adult 75 years and over: Not recommended. Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate), if transferring from another oral hypoglycaemic drug: By mouth. Adult 18 –74 years: Initially, 1mg (max. per dose 4mg), adjusted according to response, dose to be taken within 30 minutes before main meals and adjusted at intervals of 1 – 2 weeks; maximum 16mg per day. Adult 75 years and over: Not recommended.
    View full drug info
  • Gastrointestinal System Agents, Ranitidine
    Dosage form: Tablet
    Strength: 50mg, 300mg
    Indications/Special comments: Benign gastric and duodenal ulceration, gastro-oesophageal reflux, Zollinger–Ellison Syndrome, other conditions where gastric acid reduction is beneficial.
    Dosage Administration: Benign gastric and duodenal ulceration: Oral: Adult: 150mg twice daily or 300mg at night for 4 – 8 weeks, up to 6 weeks in chronic episodic dyspepsia, and up to 8 weeks in NSAID-associated ulceration (in duodenal ulcer 300mg can be given twice daily for 4 weeks to achieve a higher healing rate); maintenance, 150mg at night; Prophylaxis of NSAID-induced duodenal ulcer: Oral: Adult: 150mg twice daily. Reflux oesphagitis: Oral: Adult: 150mg twice daily or 300mg at night for up to 8 weeks, or if necessary 12 weeks (moderate to severe, 150mg 4 times daily for up to 12 weeks); long-term treatment of healed ooesphagitis, 150mg twice daily. Zollinger–Ellison Syndrome: Oral: Adult: 150mg three times daily; up to 6g daily undivided doses has been used. Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics: Oral: Adult: 150mg at onset of labour, then every 6 hours; surgical procedures,
    View full drug info
  • Gastrointestinal System Agents, Ranitidine
    Dosage form: Syrup
    Strength: 15mg/ml
    Indications/Special comments: Benign gastric and duodenal ulceration, gastro-oesophageal reflux, Zollinger–Ellison Syndrome, other conditions where gastric acid reduction is beneficial.
    Dosage Administration: See product leaflet. Peptic ulcer: Child: 2 – 4mg/kg twice daily, maximum 300mg daily.
    View full drug info
  • Cardiovascular Drugs, Rosuvastatin
    Dosage form: Tablet
    Strength: 10mg, 20mg, 40mg
    Indications/Special comments: Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis. Severe primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures, in patients with high cardiovascular risk (under expert supervision. Prevention of cardiovascular events in patients at high risk of a first cardiovascular event. Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis.
    Dosage Administration: Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures. By mouth: Adult 18–69 years: Initially, 5 – 10mg once daily, then increased if necessary to 20mg once daily, dose to be increased at intervals of at least 4 weeks. Adult (patients of Asian origin): Initially, 5mg once daily then increased if necessary up to 20mg once daily, dose to be increased at intervals of at least 4 weeks. Adult 70 years and over: Initially, 5mg once daily then increased if necessary up to 20mg once daily, dose to be increased at intervals of at least 4 weeks.Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis- By mouth: Adult: Initially, 5mg once daily, then increased if necessary up to 20mg once daily, dose to be increased at intervals of at least 4 weeks. Severe primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures, in patients with high cardiovascular risk (under expert supervision)- By mouth: Adult: Initially, 5 – 10mg once daily, increased if necessary to 20mg once daily, then increased if necessary to 40mg once daily, dose to be increased at intervals of at least 4 weeks. Prevention of cardiovascular events in patients at high risk of a first cardiovascular event- By mouth: Adult 18 – 69 years: 20mg once daily. Adult (patients of Asian origin): Initially, 5mg once daily then increased if necessary up to 20mg once daily. Adult 70 years and over: Initially, 5mg once daily then increased if necessary up to 20mg once daily. Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis. By mouth: Adult: Initially, 5mg once daily, then increased if necessary up to 20mg once daily. Initially, 5mg once daily with concomitant fibrate increased if necessary to maximum of 20mg daily.
    View full drug info
  • Cardiovascular Drugs, Ramipril
    Dosage form: Capsule
    Strength: 1.25mg, 2.5mg, 5mg, 10mg
    Indications/Special comments: Treatment of hypertension, either alone or in combination with other antihypertensive agents.
    Dosage Administration: Oral: Adult: 2.5 - 5mg once daily, maximum: 20mg/day.
    View full drug info
  • Blood products and drugs affecting blood, Rivaroxaban
    Dosage form: Tablet
    Strength: 10mg, 15mg, 20mg
    Indications/Special comments: Deep vein thrombosis prophylaxis: Deep vein thrombosis treatment: Nonvalvular atrial fibrillation. Pulmonary embolism treatment. Reduction in the risk (secondary prevention) of recurrent deep vein thrombosis and/or pulmonary embolism.
    Dosage Administration: Prophylaxis of venous thromboembolism following knee replacement surgery. Oral: Adult: 10mg once daily for 2 weeks, to be started 6 – 10 hours after surgery. Prophylaxis of venous thromboembolism following hip replacement surgery: Oral: Adult: 10mg once daily for 5 weeks, to be started 6 – 10 hours after surgery. Initial treatment of deep-vein thrombosis; Initial treatment of pulmonary embolism: Oral: Adult: Initially, 15mg twice daily for 21 days, to be taken with food. Continued treatment of deep-vein thrombosis (following initial treatment; Continued treatment of pulmonary embolism (following initial treatment); Prophylaxis of recurrent deep-vein thrombosis; Prophylaxis of recurrent pulmonary embolism: Oral: Adult: 20mg once daily, to be taken with food. Prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: congestive heart failure, hypertension, previous stroke or transient ischaemic attack, age = 75 years, or diabetes mellitus: Oral: Adult: 20mg once daily, to be taken with food. Prophylaxis of atherothrombotic events in acute coronary syndrome (with aspirin alone or aspirin and clopidogrel): Oral: Adult: 2.5mg twice daily usual duration 12 months.
    View full drug info